Soluble Fas (APO-1, CD95) and soluble Fas ligand in rheumatic diseases
โ Scribed by Kazuhisa Nozawa; Nobuhiko Kayagaki; Yoshiaki Tokano; Hideo Yagita; Ko Okumura; Hiroshi Hasimoto
- Publisher
- John Wiley and Sons
- Year
- 1997
- Tongue
- English
- Weight
- 381 KB
- Volume
- 40
- Category
- Article
- ISSN
- 0004-3591
No coin nor oath required. For personal study only.
๐ SIMILAR VOLUMES
Derailed T-cell activation can give rise to life-threatening macrophage activation, the final common pathway of the different forms of reactive macrophage activation syndromes (rMAS). Besides inappropriate activation of the immune system, impaired termination of immune responses might be another mec
To quantify soluble Fas/APO-1 (sFas/ APO-1) protein in the serum of patients with systemic lupus erythematosus (SLE) and juvenile rheumatoid arthritis (JRA). Methods. Soluble Fas/APO-1 was quantified using a sandwich enzyme-linked immunosorbent assay. Disease activity in SLE patients was assessed b
FIGURE 1 -Immunoblot analyses identify 40 kDa (Fas) and 45 kDa (FasL) proteins.